Biotech Values

[DewDiligence]

I think the NPV is lower because, as I have noted before, I think it is going to be tough to get the cash out of WPI/A*. NOT because I think that the shift to royalty arrangement killed MNTAs claim on settlement.

I agree with the second part of your statement, but not with the first part; however, our difference of opinion probably doesn’t make much difference to the bottom-line assessment of the lawsuit’s NPV for MNTA.

WPI is a co-defendant in the lawsuit; if there is eventually a legal judgment against WPI, the judgment will be collectable, IMO, irrespective of WPI’s side agreement with Amphastar re indemnification.